These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34117925)

  • 1. How should we manage non-small-cell lung cancer "not-otherwise-specified"?
    Kim YH; Nishimura Y; Funada Y
    Med Oncol; 2021 Jun; 38(7):82. PubMed ID: 34117925
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypoxic markers in non-small cell lung cancer (NSCLC) - A review.
    Xu FX; Zhang YL; Liu JJ; Zhang DD; Chen HB
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):849-52. PubMed ID: 27010140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
    Shepherd FA
    J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
    [No Abstract]   [Full Text] [Related]  

  • 4. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
    Normanno N; Di Maio M; Perrone F; Campiglio M
    J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
    [No Abstract]   [Full Text] [Related]  

  • 6. [Predictive value of the early metabolic response in patients with advanced-stage non-small cell lung cancer].
    Moreno C; Mourelo S; Soler M; Moragas M; Riera E; Garcia JR
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):324-5. PubMed ID: 24418117
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib has the potential of activating cell immunity against malignant cells.
    Kanazawa S; Muramatsu M; Kinoshita Y; Yamaguchi K; Nomura S
    J Clin Oncol; 2005 Jun; 23(16):3865-6; author reply 3866-7. PubMed ID: 15923592
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarker strategy in lung cancer.
    Esencay M; Watson A; Mukherjee K; Hanicq D; Gubernick SI
    Nat Rev Drug Discov; 2018 Jan; 17(1):13-14. PubMed ID: 28959953
    [No Abstract]   [Full Text] [Related]  

  • 9. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 10. First-Line Immune Therapy-Implications for Pathologists.
    Miller RA; Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2016 Aug; 140(8):739-40. PubMed ID: 27472228
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to G. Spitzer and M.A. Socinski.
    Zer A; Leighl NB
    J Clin Oncol; 2015 Feb; 33(5):525-6. PubMed ID: 25584009
    [No Abstract]   [Full Text] [Related]  

  • 12. The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.
    Lonardo F; Li X; Kaplun A; Soubani A; Sethi S; Gadgeel S; Sheng S
    Curr Pharm Des; 2010 Jun; 16(16):1877-81. PubMed ID: 20337574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.
    Spitzer G; Socinski MA
    J Clin Oncol; 2015 Feb; 33(5):522-3. PubMed ID: 25584003
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonsmall cell lung cancer.
    Sculier JP
    Eur Respir Rev; 2013 Mar; 22(127):33-6. PubMed ID: 23457162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas.
    Kawaguchi T; Ando M; Kubo A
    J Clin Oncol; 2015 Feb; 33(5):526-7. PubMed ID: 25584006
    [No Abstract]   [Full Text] [Related]  

  • 16. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
    J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarkers of response to gefitinib in non-small-cell lung cancer.
    Carbone DP
    Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
    [No Abstract]   [Full Text] [Related]  

  • 18. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.
    Remark R; Becker C; Gomez JE; Damotte D; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH; Powell CA; Altorki NK; Merad M; Gnjatic S
    Am J Respir Crit Care Med; 2015 Feb; 191(4):377-90. PubMed ID: 25369536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
    Berge EM; Doebele RC
    Semin Oncol; 2014 Feb; 41(1):110-25. PubMed ID: 24565585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targeted agents and biologic therapies for non-small cell lung cancer.
    Somaiah N; Simon GR
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S434-54. PubMed ID: 21102235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.